Farallon co-chief investment officer Andrew Spokes
April 5, 2023 10:31 AM EDTUpdated 07:16 PM
People

Hedge fund slams Ex­elix­is for R&D man­age­ment, launch­es proxy fight for board seats (up­dat­ed)

Kyle LaHucik

Senior Reporter

A hedge fund is look­ing to re­fresh Ex­elix­is, propos­ing three board di­rec­tor nom­i­nees and launch­ing a proxy bat­tle that’s scru­ti­niz­ing the biotech’s R&D blue­print. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times